Vectus Biosystems (ASX:VBS) Other Gross PPE : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Other Gross PPE?

Vectus Biosystems's Other Gross PPE for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Vectus Biosystems's annual Other Gross PPE declined from Jun. 2021 (A$0.02 Mil) to Jun. 2022 (A$0.00 Mil) but then stayed the same from Jun. 2022 (A$0.00 Mil) to Jun. 2023 (A$0.00 Mil).

Vectus Biosystems Other Gross PPE Historical Data

The historical data trend for Vectus Biosystems's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Other Gross PPE Chart

Vectus Biosystems Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Other Gross PPE

Get a 7-Day Free Trial

0.06

0.02

Vectus Biosystems Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Gross PPE	Get a 7-Day Free Trial											-	-	-	-	-

Vectus Biosystems Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Vectus Biosystems (ASX:VBS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018

Website

https://www.vectusbiosystems.com.au

Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines